ArisGlobal launches XDI, a federated data intelligence platform designed to unify life sciences data and deliver explainable, enterprise-wide AI decisions.
ArisGlobal, an AI-focused technology company serving the life sciences industry and creator of LifeSphere®, has introduced XDI, its new Data Intelligence Cortex platform. Announced at the company’s Breakthrough 2026 event, XDI is designed to transform regulated life sciences data into continuous, explainable, decision-grade intelligence across the product lifecycle.
The launch comes as pharmaceutical and biotechnology companies grapple with the growing volume of fragmented data spread across disconnected systems. The challenge, increasingly, is not access to information but generating consistent, defensible decisions from it.
Unlike traditional approaches that consolidate data into a single repository, XDI uses a federated model, bringing intelligence to data wherever it resides. The platform connects signals across domains, applies contextual learning, and delivers insights directly into operational workflows, enabling organizations to move from reactive compliance to anticipatory risk management.
By federating meaning across systems, XDI enables auditable and explainable cross-domain reasoning spanning clinical development, pharmacovigilance, regulatory affairs, medical affairs, quality, and benefit-risk management.
“Life sciences organizations are no longer asking whether to adopt AI, but how to operationalize it at scale,” said Aman Wasan, chief executive officer of ArisGlobal. “XDI is designed to deliver decision-grade intelligence by recommending actions and explaining the reasoning behind them — enabling confident, regulator-ready decisions.”
Also Read: Building AI That Compounds, Not Just Ships
Initial Focus Areas
XDI’s first phase targets three operational domains:
- Pharmacovigilance Operational Intelligence — Aims to shift safety operations from reactive to proactive, with early concept evaluations indicating up to 70–80% reduced compliance effort and a 75% reduction in inline quality control through continuous checks.
- Benefit-Risk Intelligence — Designed to accelerate evidence-driven signal management, with early findings suggesting more than 30% faster signal detection, up to 40% noise reduction in workflows, and compression of review cycles from several weeks to days.
- Regulatory Operational Intelligence — Provides cross-domain and real-world data insights, with projected compliance effort reductions similar to those seen in pharmacovigilance pilots.
Also Read: The Missing Layer in AI’s Enterprise Ambition
The platform is built on what ArisGlobal calls a “Trust by Design” framework, integrating AI governance controls and embedded auditability through its NavaX governance layer to support regulatory defensibility across the AI lifecycle.
All performance metrics cited reflect directional outcomes from early concept evaluations.
ArisGlobal provides cloud-based software for pharmacovigilance, regulatory affairs, quality management, and medical affairs, serving more than 300 life sciences customers globally.
